CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus

CareDx, Inc.CDNA is expected to release third-quarter 2026 results soon.

In the last reported quarter, the company posted adjusted earnings per share (EPS) of 37 cents, which surpassed the Zacks Consensus Estimate by 68.18%. CareDx's earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 85.66%.

CDNA's Q3 Estimates

The Zacks Consensus Estimate for revenues is pegged at $122.4 million, indicating an increase of 22.3% from the year-ago figure.

The Zacks Consensus Estimate for EPS is pinned at 24 cents, implying a decline of 14.3% from the year-ago figure.

Estimate Revision Trend Ahead of CDNA's Q3 Earnings

Estimates for third-quarter earnings have remained unchanged in the past 60 days.

Here's a brief snapshot of the pet healthcare innovator's performance leading up to the announcement.

Key Drivers of CDNA's Q3 Performance

The company is likely to have sustained its growth momentum in the third quarter of 2026, supported by higher Testing Services revenues and continued expansion of Patient and Digital Solutions revenues. Strong demand across transplant programs, favorable reimbursement dynamics and increases in testing activity across both surveillance and for-cause settings are expected to have boosted the third-quarter top line.

Several strategic developments are also expected to have supported CareDx's revenue growth. In line with this, the divestiture of the Lab Products business to Eurobio Scientific must have allowed the company to focus on its core molecular diagnostics operations, while the acquisition of Naveris might have expanded its presence in specialty oncology through the NavDx test for molecular surveillance of HPV-driven cancers.

Meanwhile, the finalization of Medicare coverage for AlloSure and AlloMap strengthened reimbursement visibility for transplant surveillance testing, while AlloHeme's clinical validation progress and planned CLIA readiness in 2026 supported CareDx's expansion into cell therapy diagnostics, with commercial launch targeted for 2027.

CDNA's strong financial position and operational capabilities are likely to have supported continued business expansion. In the second quarter of 2026, cash collections increased 49% year over year to $136 million, while operating cash flow reached $31 million. The company ended the quarter with $374 million in cash and cash equivalents and no debt, providing financial flexibility to support its growth initiatives. Approximately 90% of transplant test volume was electronically connected through integrated electronic medical records or CareDx's care portal, supporting workflow efficiency. We expect these trends to have persisted in the third quarter as well.